Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB/c mice compared to that of the first-line regimen and have yielded promising results in in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Antimicrob Agents Chemother
Main Authors: Xu, Jian, Li, Si-Yang, Almeida, Deepak V., Tasneen, Rokeya, Barnes-Boyle, Kala, Converse, Paul J., Upton, Anna M., Mdluli, Khisimuzi, Fotouhi, Nader, Nuermberger, Eric L.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2019
Teme:
Experimental Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496099/
https://ncbi.nlm.nih.gov/pubmed/30833432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00021-19
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki